Establishment of documents under evaluation for Edaravone and Dexborneol concentrated solution for injection and evaluation of drug use rationality
Objective To establish documents under evaluation(DUE)for Edaravone and Dexborneol concentrated solution for injection,and to evaluate its drug use rationality.Methods Based on the instructions of the Edaravone and Dexborneol concentrated solution for injection,and based on the actual application situation and relevant diagnosis and treatment guidelines of Taian Hospital of Traditional Chinese Medicine in Shandong Province,DUE standards were formulated.141 medical records that met the standards from January 2022 to August 2023 were selected,and the drug use rationality was evaluated using the attribute hierarchical model(AHM).Results Among 141 medical records,the proportion of irrational indications was 14.17%,the proportion of irrational usage and dosage was 12.77%,the proportion of irrational solvents was 1.42%,the proportion of irrational compatibility contraindications was 2.84%,the proportion of irrational contraindications was 6.38%,the proportion of irrational combination therapy was 9.22%,the proportion of irrational treatment courses was 4.96%,the proportion of irrational clinical efficacy evaluation was 7.09%,unreasonable monitoring of adverse reactions accounted for 4.96%,the proportion of irrational medication monitoring was 2.84%,and the proportion of irrational physician authority indicators was 2.13%.Conclusion There are some irrational use of edaravone dexcamphorol injection concentrated solution during clinical application,which should be paid attention to by clinicians and pharmacists.
Edaravone and Dexborneol concentrated solution for injectionDocuments under evaluationDrug use rationalityIndications
万方数据
维普
